**OVERVIEW** We are planning for in vitro exploration (Milestone Phase I) first to validate biofield therapy in the new cell lines not previously tested, followed by in vitro mechanistic validation (Milestone Phase II). In Phase I we will also test treatment using distant biofield therapy and sound-based biofield therapy. The in vivo evaluation will be initiated following Milestones I and II (Milestone Phase III). The following will be measured in phases I, II, and III. **In vitro Phase I**: Cell proliferation and survival will be determined in HCC and PDAC cells treated with local and distance biofield therapists and the prerecorded sound. Human breast cancer MDA-MB-231 cells and mouse lung carcinoma LLC cells will be used as positive control. The determination of biomarkers relevant cell signaling, epigenetic modification, and cancer stemness will be carried out in the cells treated with biofield therapy locally during this phase of study. The cells treated with distance biofield therapy and sound therapy for the biomarker measurement will be collected and stored until future analysis when the advisory board deems appropriate. - Cell proliferation and survival to determine the effect of biofield therapy in phenotypical change of cancer cells. - Epigenetic biomarkers and cell signaling of certain hallmark pathways to see if we can determine correlation between biofield therapy and pathway activation, which may lead to an understanding of biological mediators and/or mechanism by which subtle energy improves cancer outcomes. - Cell proliferation and survival to determine the effect of biofield therapy in phenotypical change of cancer cells. - Epigenetic biomarkers and cell signaling of certain hallmark pathways to see if we can determine correlation between biofield therapy and pathway activation, which may lead to an understanding of biological mediators and/or mechanism by which subtle energy improves cancer outcomes. - Cancer stem cell markers to evaluate the effect of biofield therapy on the stemness of cancer cells. - Cell proliferation and survival with faraday cage to identify the mechanism of biofield therapy in cancer biology. - EEG of the biofield therapists at first session. - Energy healer dosage. - Testing in person, distant, and sound delivery techniques. - Conducting trials where we block electromagnetic fields with modified faraday boxes. **In vitro Phase II** - Validation of potential mechanisms by modifying the markers/pathways or by pharmacological intervention of those pathways that are most influenced by biofield therapy to confirm which targets/pathways are most important for biofield therapy’s impact on cancer biology. CRISPR/Cas9, a versatile and precise method for genetic modification, will be used to alter the target genes in HCC and PDAC cells. Dr. Yang’s laboratory has used this technique for knocking down the gene of interest in other study. - The details for this phase of the research plan are not included in this proposal because the design of the study will depend on the outcome of the Phase 1A, but the budget has been included in the first year of the study. - EEG of the biofield therapists at first session. **In vivo Phase III** - Survival study of mice bearing HCC or PDAC tumor with both healers. - Mouse and healer EEG using the Baylor technology to see if there is a correlation/synchrony with biofield therapist EEG and behavior. - EEG of the biofield therapists at multiple points over time.